par Abramowicz, Daniel 
;Goldman, Michel ;De Pauw, Luc ;Doutrelepont, Jean-Marc ;Kinnaert, Paul ;Vanherweghem, Jean-Louis ;Vereerstraeten, Pierre
Référence The New England journal of medicine, 324, page (1438-1439)
Publication Publié, 1991
;Goldman, Michel ;De Pauw, Luc ;Doutrelepont, Jean-Marc ;Kinnaert, Paul ;Vanherweghem, Jean-Louis ;Vereerstraeten, Pierre Référence The New England journal of medicine, 324, page (1438-1439)
Publication Publié, 1991
Lettre à l'éditeur
| Résumé : | To the Editor: Swinnen et al. (Dec. 20 issue) reported an 11.4 percent incidence of post-transplantation lymphoproliferative disorder associated with the administration of OKT3 in heart-transplant recipients.1 This experience is not consistent with that at the Minneapolis Heart Institute, where a prophylactic OKT3 regimen has been used in high-risk heart-transplant recipients for 45 months.2 Since May 3, 1987, 39 recipients of heart transplants have received OKT3; 31 were weaned from steroids three to six months after transplantation and have been maintained on a steroid-free regimen of cyclosporine and azathioprine. One- and three-year survival rates were 93 percent and 91 percent,. . . © 1991, Massachusetts Medical Society. All rights reserved. |
